The patients’ perspective on botulinum neurotoxin A treatment: results of a multinational survey for patients with spasticity.

2019-03-06T17:54:43+00:00 March 6th, 2019|News, Publications|

  • Presented at TOXINS 2019

  • Collaborator: Ipsen

  • Authors: Bahroo L, Patel A, Wein T, Wilczynski O, Rios C, Murie-Fernandez M

Management strategies for adult spasticity include physical and pharmacological therapies, as well as surgery in severe or intractable cases. Botulinum toxin type A (BoNT-A) is a recommended pharmacological option for patients with spasticity, and its anti-spastic effects have been demonstrated in stroke and central nervous system lesions, multiple sclerosis and cerebral palsy. The aim of this study is to understand the burden of BoNT-A treatment from the patient perspective, in terms of impact on activities of daily living and quality of life.